Search details
1.
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
N Engl J Med
; 384(18): 1705-1718, 2021 05 06.
Article
in English
| MEDLINE | ID: mdl-33951360
2.
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
Am J Respir Crit Care Med
; 207(7): 929-935, 2023 04 01.
Article
in English
| MEDLINE | ID: mdl-36455068
3.
Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832.
Antimicrob Agents Chemother
; 67(6): e0147722, 2023 06 15.
Article
in English
| MEDLINE | ID: mdl-37219453
4.
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Antimicrob Agents Chemother
; 67(10): e0068323, 2023 10 18.
Article
in English
| MEDLINE | ID: mdl-37768317
5.
Resistance to Mycobacterium tuberculosis Infection Among Household Contacts: A Multinational Study.
Clin Infect Dis
; 73(6): 1037-1045, 2021 09 15.
Article
in English
| MEDLINE | ID: mdl-33772550
6.
Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis.
Antimicrob Agents Chemother
; 65(2)2021 01 20.
Article
in English
| MEDLINE | ID: mdl-33229425
7.
Increased bactericidal activity but dose-limiting intolerability at 50â mg·kg-1 rifampicin.
Eur Respir J
; 58(1)2021 07.
Article
in English
| MEDLINE | ID: mdl-33542056
8.
Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial.
BMC Infect Dis
; 21(1): 205, 2021 Feb 24.
Article
in English
| MEDLINE | ID: mdl-33627075
9.
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.
Antimicrob Agents Chemother
; 64(4)2020 03 24.
Article
in English
| MEDLINE | ID: mdl-31988102
10.
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Am J Respir Crit Care Med
; 191(9): 1058-65, 2015 May 01.
Article
in English
| MEDLINE | ID: mdl-25654354
11.
Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment".
Antimicrob Agents Chemother
; 64(7)2020 06 23.
Article
in English
| MEDLINE | ID: mdl-32366714
12.
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.
J Antimicrob Chemother
; 70(5): 1558-66, 2015 May.
Article
in English
| MEDLINE | ID: mdl-25630641
13.
Phase II dose-ranging trial of the early bactericidal activity of PA-824.
Antimicrob Agents Chemother
; 56(6): 3027-31, 2012 Jun.
Article
in English
| MEDLINE | ID: mdl-22430968
14.
High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis.
Pediatr Infect Dis J
; 41(5): e194-e202, 2022 05 01.
Article
in English
| MEDLINE | ID: mdl-35239624
15.
A Step toward an Optimized Rifampin Dose Completed.
Am J Respir Crit Care Med
; 192(4): 525-6, 2015 Aug 15.
Article
in English
| MEDLINE | ID: mdl-26278799
16.
Central monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosis.
Contemp Clin Trials
; 104: 106355, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33713841
17.
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients.
Antimicrob Agents Chemother
; 54(8): 3402-7, 2010 Aug.
Article
in English
| MEDLINE | ID: mdl-20498324
18.
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Lancet Infect Dis
; 17(1): 39-49, 2017 01.
Article
in English
| MEDLINE | ID: mdl-28100438
Results
1 -
18
de 18
1
Next >
>>